Support our Foundation of Myology project
Led by Simone Birnbaum, a researcher at the Neuromuscular physiology and neuromuscular Evaluation Lab, in collaboration with the AFM-Telethon, the national MYaEX study involved 455 adults with autoimmune myasthenia gravis, which was stabilised by treatment in more than half of…
South African clinicians have compiled and analysed the difficulties in accessing innovative treatments for SMN1-related proximal spinal muscular atrophy in much of the non-Western world: their work is based on an exhaustive literature review covering the period 2014–2025, though limited…
Researchers in Lyon have investigated, both in vitro and in vivo, the potential therapeutic synergy between the type 6 HDAC inhibitor (givinostat), which is already used to combat muscle atrophy in Duchenne muscular dystrophy, and nusinersen, which is already marketed…
On 31 March 2026, the European Commission granted a marketing authorisation (MA) under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of mitochondrial myopathies with thymidine kinase 2 (TK2) deficiency, following the favourable opinion issued by the CHMP…
A group of European specialists in autoimmune myasthenia gravis set out to reach a consensus on the inclusion of new molecules (such as neonatal Fc receptor complement inhibitors, etc.) within the therapeutic arsenal for the disease: the first step involved…
German clinicians have investigated the benefits of the ketogenic diet (very high in fat and low in carbohydrates) in autoimmune myasthenia gravis, following on from other trials – some of which were successful – in other autoimmune diseases: 41 adults…
Two German researchers investigated the benefits and potential complications – particularly cardiovascular ones – of a new class of drugs used to treat refractory forms of autoimmune myasthenia gravis: 1,094 patients with myasthenia gravis treated with C5 inhibitors were compared…
The management of neurodevelopmental and psychiatric disorders represents a major unmet need among patients with Duchenne muscular dystrophy (DMD). As part of the European BIND (Brain Involvement iN Dystrophinopathies) project, five specialist European clinicians reported on their experience in managing…
Pioglitazone, a selective agonist of the nuclear PPAR-γ receptors, was evaluated in a phase I trial involving 13 patients with inclusion body myositis, all of whom received the treatment for 8 months following a 4-month observation period. This trial aimed…
Very late-onset autoimmune myasthenia (VLOM) is becoming increasingly common: appears from the age of 65 onwards, is characterised by a male predominance and a rare association with thymoma, should be considered in any elderly patient presenting with recent localised or…
The registration of risdiplam (Evrysdi) film-coated tablets in the French Official Journal has just been published. This new formulation will be available in pharmacies from 9 June 2026. It is indicated for patients with type I, II or III spinal…
Come and build up your knowledge! To mark the 4th edition of Muscle Week, the Institute of Myology is opening its doors on Saturday 6 June, from 10.00 am to 5.00 pm. Come and meet our scientific experts, doctors and…
New guidelines for the diagnosis and management of calpainopathies (LGMD R1 and LGMD D4) have recently been published with a view to optimising clinical practice and reducing the time to diagnosis, as part of a new National Diagnostic and Care…
With just one month to go until the 2026 session of the AcadeMYO Summer School, we take a look back at the educational activities in which the Institute is involved, aimed at all those with an interest in myology. The…
GNR-100 could be the first generic version of Spinraza for SMN1-related proximal spinal muscular atrophy. A Russian study has demonstrated bioequivalence between the two products, both of which contain the active ingredient nusinersen sodium (an antisense oligonucleotide). Comparative analyses have…
Laurence Tiennot-Herment, President of the Myology Institute Association, Sébastien Vial, Director General of Orléans University Hospital, and Sébastien Ringuedé, Vice-President in charge of the Training and University Life Committee at the University of Orléans, formalised their intention this morning at…
Muscles lie at the heart of all the major challenges facing our modern societies: the prevention of common, serious and disabling conditions; the fight against a sedentary lifestyle; adapting to changes in lifestyle; ageing and independence; and therapeutic innovation. They…
Muscle is now recognized as an essential organ for health at every stage of life, from before birth and into old age. It lies at the heart of major challenges facing modern societies: preventing common, serious and disabling conditions; combating sedentary lifestyles; adapting to changing ways of living; supporting ageing and independence; and driving therapeutic innovation. To strengthen this awareness and…
The Association Institut de Myologie and the Foch-IMM Group (Foch Hospital and Institut Montsouris) have announced that they have entered into a strategic partnership aimed at promoting myology – the science and medicine of muscle – and developing clinical research, as well as the study and…
The European reference network EURO-NMD conducted a survey to assess the needs and processes involved in the transition of patients with a neuromuscular disorder from childhood to adulthood: 67 healthcare professionals from twenty different European countries took part in this…